NervGen Pharma Corp. (NGEN)
2.00
+0.14
(+7.53%)
USD |
NASDAQ |
Aug 24, 16:00
2.03
+0.03
(+1.50%)
Pre-Market: 08:24
NervGen Pharma Enterprise Value : 151.65M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 151.65M |
| August 21, 2026 | 136.75M |
| August 20, 2026 | 126.11M |
| August 19, 2026 | 125.05M |
| August 18, 2026 | 120.79M |
| August 17, 2026 | 117.60M |
| August 14, 2026 | 123.45M |
| August 13, 2026 | 126.11M |
| August 12, 2026 | 126.11M |
| August 11, 2026 | 123.98M |
| August 10, 2026 | 119.73M |
| August 07, 2026 | 120.79M |
| August 06, 2026 | 121.86M |
| August 05, 2026 | 117.60M |
| August 04, 2026 | 115.47M |
| August 03, 2026 | 113.34M |
| July 31, 2026 | 111.22M |
| July 30, 2026 | 109.09M |
| July 29, 2026 | 108.02M |
| July 28, 2026 | 110.15M |
| July 27, 2026 | 113.34M |
| July 24, 2026 | 112.28M |
| July 23, 2026 | 117.07M |
| July 22, 2026 | 121.86M |
| July 21, 2026 | 128.24M |
| Date | Value |
|---|---|
| July 20, 2026 | 122.92M |
| July 17, 2026 | 116.54M |
| July 16, 2026 | 116.54M |
| July 15, 2026 | 118.66M |
| July 14, 2026 | 123.98M |
| July 13, 2026 | 144.20M |
| July 10, 2026 | 138.88M |
| July 09, 2026 | 136.75M |
| July 08, 2026 | 135.69M |
| July 07, 2026 | 152.72M |
| July 06, 2026 | 163.36M |
| July 02, 2026 | 164.42M |
| July 01, 2026 | 161.23M |
| June 30, 2026 | 158.04M |
| June 29, 2026 | 146.88M |
| June 26, 2026 | 139.59M |
| June 25, 2026 | 142.83M |
| June 24, 2026 | 149.31M |
| June 23, 2026 | 154.98M |
| June 22, 2026 | 161.45M |
| June 18, 2026 | 166.31M |
| June 17, 2026 | 165.50M |
| June 16, 2026 | 150.12M |
| June 15, 2026 | 138.78M |
| June 12, 2026 | 143.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | -0.0413M |
| Milestone Pharmaceuticals, Inc. | 100.70M |
| Clearmind Medicine, Inc. | -11.80M |
| Lexaria Bioscience Corp. | 13.49M |
| Target Group, Inc. (Canada) | 11.80M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.10M |
| Total Expenses (Quarterly) | 21.10M |
| EPS Diluted (Quarterly) | -0.2283 |
| Earnings Yield | -26.80% |
| Normalized Earnings Yield | -17.40 |